Kairos Pharma ratios data for the quarter ended Dec 2025. These financial ratios cover 9 quarters of results from Sep 2023 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Ratios | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Dec2025 |
|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||
| EBT Margin | -1.26% | ||||||||
| EBIT Margin | -1.27% | ||||||||
| EBITDA Margin | -1.27% | ||||||||
| Operating Margin | -1.27% | ||||||||
| Net Margin | -1.26% | ||||||||
| FCF Margin | -0.71% | ||||||||
| Efficiency | |||||||||
| Assets AverageAssets Avg. | 5.39M | 6.85M | 7.30M | 6.61M | |||||
| Invested CapitalInvested Cap. | 4.12M | ||||||||
| Leverage & Solvency | |||||||||
| Interest Coverage RatioInterest Cover | -19.13 | -363.00 | -17.94 | -18.50 | -0.71 | -10.87 | |||
| Debt Ratio | 0.16 | ||||||||
| Times Interest Earned | -19.13 | -363.00 | -17.94 | -18.50 | -0.71 | -10.87 | |||
| Valuation | |||||||||
| Price to EarningsP/E | -21.92 | -10.93 | -11.79 | -8.86 | |||||
| Price to SalesP/S | 0.15 | ||||||||
| Price to BookP/B | 6.05 | 3.61 | 2.09 | 2.10 | 0.15 | ||||
| Enterprise Value | 16.95M | 13.13M | 8.88M | 7.85M | 9.45M | ||||
| EV to EBIT | -44.26 | -9.08 | -7.01 | -5.39 | |||||
| EV to EBITDA | -44.26 | -9.08 | -7.01 | -5.39 | |||||
| Market Capitalization | 20.17M | 17.26M | 14.88M | 12.60M | 14.78M | ||||
| Price to FCFP/FCF | -9.98 | -9.57 | -20.83 | -15.65 | |||||
| EV to FCF | -8.39 | -7.28 | -12.44 | -9.75 | |||||
| EV to CFO | -8.39 | -7.28 | -12.44 | -9.75 | |||||
| Return Ratios | |||||||||
| Return on Sales [ROS]ROS | -1.27% | ||||||||
| Return on Capital Employed [ROCE]ROCE | -53.21% | -54.85% | -68.65% | ||||||
| Return on Assets [ROA]ROA | -56.37% | -58.30% | -70.95% |